Main Menu

The developed technology is a high-affinity polyclonal antibody targeting BST-2, a crucial surface antigen involved in restricting the replication of HIV-1 and other enveloped viruses. This antibody, generated from recombinant BST-2 ectodomain protein, offers versatility in various research techniques, such as FACS, immunoblotting, immunofluorescence, and immunoprecipitation. Additionally, it exhibits bioactivity, effectively inhibiting BST-2 function in virus-producing cells.

This groundbreaking technology entails the utilization of genetically modified mice, specifically engineered to enable the non-destructive detection and isolation of cells actively transcribing the IL-4 and IL-13 genes. By expressing Amcyan and DsRed-DR fluorescent proteins under the control of these gene loci, researchers gain a powerful tool for studying cytokine gene expression without the need for cell death, offering significant advantages over traditional intracellular staining methods.

This technology introduces a groundbreaking method for discovering and isolating anti-idiotypic antibodies, with a primary focus on inhibiting or extinguishing the activity of VRCOl, a broadly neutralizing anti-HIV-1 antibody. These anti-idiotypic antibodies provide a vital mechanism for controlling adverse events that may result from therapeutic antibody administration. The innovative method involves immunizing animals with specific antibody fragments, followed by systematic selection and isolation of somatically mutated B cells.

This technology presents a sophisticated two-step vaccination approach designed to provide comprehensive protection against filovirus infections, including Ebola and Marburg viruses. It involves administering a prime-boost vaccine sequence, employing replication-defective adenoviral serotype 26 (Ad26) as the priming agent and replication-defective adenoviral serotype 35 (Ad35) as the boosting agent. Both vectors are engineered to express the crucial filovirus envelope glycoprotein (GP), encompassing various strains of Ebolavirus (EBOV) and Marburg (MAR).

This groundbreaking technology introduces a highly potent, human anti-HIV antibody that targets a novel epitope, surpassing the efficacy of existing anti-HIV antibodies. With a prolonged half-life, it offers versatile applications, including early-stage HIV treatment, newborn prophylaxis, and vaccine development validation. Collaborative efforts aim to harness its potential for antibody-dependent cell-mediated cytotoxicity (ADCC) against HIV-infected cells.

The technology involves the development of monoclonal antibodies produced by hybridomas, including cell lines such as 10G3, 3E6, 10D4, 10G4, 1D8, 13D10, 9E5, and 9F10, which specifically react with Bacillus anthracis Lethal Factor (LF). These monoclonal antibodies offer valuable applications in anthrax detection, therapeutic intervention, and research into the biology of Bacillus anthracis and its lethal toxin. This advancement provides promising tools for mitigating the impact of anthrax infections and advancing our understanding of this deadly pathogen.

This technology includes a large panel of monoclonal antibodies (mAbs) against the spike glycoprotein, capable of recognizing intact SARS-CoV-2 virions with high affinity. Data to support SARS-CoV-2-specific binding include ELISA and label-free (biolayer interferometry) binding measurements using recombinant proteins, immunofluorescence in culture, immunofluorescence staining of tissue from infected patients, and virus neutralization assays.

This technology includes a Dengue-2 isolated virus for use as a cancer vaccine therapeutic.

This technology includes Streptococcus pneumoniae isolates collected through CDC’s Global Strain Bank project with particular serotypes. They were collected as part of routine clinical and surveillance activities and have a wide variety of uses including research, diagnostic, and the development of therapeutics.

Summary:

The National Cancer Institute (NCI) seeks licensees to further develop novel exonuclease VII (ExoVII) inhibitors as antibiotic adjuvants for enhancing the efficacy of quinolone antibiotics, particularly in quinolone-resistant bacterial infection.